AbCellera Biologics Inc.
ABCLNext catalyst
ABCL635
Vasomotor Symptoms Associated With Menopause
Get an email about ABCL's next catalysts
Track AbCellera Biologics (ABCL) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
ABCL Earnings Report
EPS Est: $-0.18 | FQ end Sep/2026 | Call: amc
ABCL635 Phase 2 Est. Readout
Primary completion for ABCL635 trial (NCT07118891) in Vasomotor Symptoms Associated With Menopause
SourceMarket Overview
Stock performance and key metrics
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
WebsiteBamlanivimab
COVID-19
LY3832479
COVID-19
LY3853113
COVID-19
ABCL635
Vasomotor Symptoms Associated With Menopause
Etesevimab
COVID-19
Bebtelovimab
COVID-19
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Bamlanivimab | Phase 3 | COVID-19 | - | - |
LY3832479 | Phase 3 | COVID-19 | - | - |
LY3853113 | Phase 3 | COVID-19 | - | - |
ABCL635 | Phase 2 | Vasomotor Symptoms Associated With Menopause | - | - |
Etesevimab | Phase 2 | COVID-19 | - | - |
Bebtelovimab | Phase 2 | COVID-19 | - | - |
Frequently asked questions
What is in AbCellera Biologics Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in AbCellera Biologics Inc.'s (ABCL) pipeline across Phase 3, Phase 2. Its lead program is Bamlanivimab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is AbCellera Biologics Inc.'s next FDA catalyst?→
AbCellera Biologics Inc.'s (ABCL) next tracked catalyst is a Phase 2 readout expected February 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ABCL biotech catalysts?→
Add ABCL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow AbCellera Biologics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.